Implantable self-inflating attenuation device

• US 6,988,983 B2
• Filed: 03/17/2003
• Issued: 01/24/2006
• Est. Priority Date: 04/14/2000
• Status: Expired due to Term

• Current Assignee: Solace Therapeutics, Inc.
• Original Assignee: Solace Therapeutics, Inc.
• Inventors: Connors, Kevin G., Yurek, Matthew T., Nguyen, Khoi M., Pintauro, William L., Cao, Hung H., Wallin, Sheila K., Kilcoyne, John T.
• Primary Examiner(s): Lacyk, John P.
• Application Number:
  US10/391,450
• Publication Number:
  US 20030229264A1
• Time in Patent Office: 1,044 Days
• Field of Search: 600 29- 32, 128897- 98, 446/221, 441/31, 441/98
• US Class Current: 600/29
• CPC Class Codes: A61B 5/205 Determining bladder or urethral pressure
• CPC Class Codes: A61F 2/0027 inflatable
• CPC Class Codes: A61F 2/042 Urinary bladders
• CPC Class Codes: A61F 2/06 Blood vessels
• CPC Class Codes: A61F 2002/068 Modifying the blood flow model, e.g. by diffuser or deflector
• CPC Class Codes: A61M 2025/0076 Unidirectional valves
• CPC Class Codes: A61M 2210/1078 Urinary tract
• CPC Class Codes: A61M 2210/1085 Bladder
• CPC Class Codes: A61M 25/10 Balloon catheters A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02; inflatable balloons for placing stents or stent-grafts A61F2/958 ; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00
• CPC Class Codes: A61M 25/1002 characterised by balloon shape A61M25/1006, A61M25/1009 take precedence

Abstract

Disclosed herein is an attenuation device comprising a flexible housing and a medium capable of transformation to inflate the housing from the first configuration to the second configuration. Also disclose herein are methods of treating a patient, comprising: providing a self-inflating expandable attenuation device, containing a medium which is transformable from a first, reduced volume to a second, expanded volume; positioning the attenuation device within the patient at a treatment site; and transforming the medium from the first volume to the second volume. In one embodiment, a self-inflating expandable attenuation device is used to treat urinary tract dysfunction. In another embodiment, a self-inflating expandable attenuation device is used to treat benign hypertrophy of the prostate.

Claims

1. An attenuation device, comprising:

a flexible housing, defining a chamber therein, the housing inflatable from a first, deflated configuration to a second, at least partially inflated configuration, the first configuration facilitating introduction of the device into a patient'"'"'s bladder, the second configuration facilitating attenuation of pressure changes in the bladder;

a chemical medium capable of a transformation to inflate the housing from the first configuration to the second configuration; and

an initiator, for initiating the transformation;

wherein the chemical medium and the initiator are initially physically separated from each other; and

wherein a chemical reaction occurs within the device when the chemical medium comes into contact with the initiator, thereby causing the housing to inflate from the first configuration to the second configuration.

2. An attenuation device as in claim 1, wherein the transformation comprises reacting to produce a gas reaction product.

3. An attenuation device as in claim 1, further comprising a barrier for separating the chemical medium and the initiator.

4. An attenuation device as in claim 3, wherein a mechanical barrier separates the chemical medium and the initiator.

5. An attenuation device as in claim 3, wherein the transformation occurs in response to disrupting the barrier.

6. An attenuation device an in claim 3, wherein the barrier comprises a breakable wall defining a container for containing the initiator.

7. An attenuation device as in claim 6, wherein the breakable wall is contained within the chamber.

8. An attenuation device as in claim 6, wherein the breakable wall is in communication with the chamber.

9. An attenuation device as in claim 1, wherein the initiator is contained within a breakable container.

10. An attenuation device as in claim 1, wherein one of the chemical medium and the initiator includes a carbonate.

11. An attenuation device as in claim 10, wherein the chemical medium or the initiator includes an acid.

12. A method of treating a patient, comprising the steps of:

providing an expandable attenuation device, containing a medium which is transformable from a first, reduced volume to a second, expanded volume;

positioning the attenuation device within the patient at a treatment site;

end

transforming the medium from the first volume to the second volume.

13. A method of treating a patient as in claim 12, wherein the second volume is at least 5 times the first volume.

14. A method of treating a patient as in claim 12, wherein the second volume is at least 50 times the first volume.

15. A method of treating a patient as in claim 12, wherein the second volume is at least 400 times the first volume.

16. A method of treating a patient as in claim 12, wherein the transforming step comprises exposing a chemical to an initiator.

17. A method of treating a patient as in claim 16, wherein the exposing step produces a gas phase reaction product.

18. A method of treating a patient as in claim 16, wherein the exposing step comprises disrupting a barrier between the chemical and the initiator.

19. A method of treating a patient as in claim 12, wherein the positioning step comprises positioning the attenuation device in a body cavity.

20. A method of treating a patient as in claim 19, wherein the body cavity comprises the bladder.

21. A method of treating a patient as in claim 19, wherein the body cavity comprises the urethra.

22. A method of treating a patient as in claim 12, wherein the positioning step comprises positioning the attenuation device in between adjacent tissue planes.

23. A method of treating a patient as in claim 12, wherein the positioning step comprises positioning the attenuation device within solid tissue.

24. A method of treating urinary tract dysfunction, comprising the steps of:

identifying a patient exhibiting symptoms of urinary tract incontinence;

providing an expandable attenuation device, containing a medium which is transformable from a first, reduced volume to a second, expanded volume;

transurethrally introducing the attenuation device within the patient'"'"'s bladder; and

transforming the medium from the first volume to the second volume to treat the patient.

25. A method of treating a patient who has benign hypertrophy of the prostate, comprising the steps of:

identifying a patient exhibiting symptoms of benign hypertrophy of the prostate;

providing an expandable attenuation device, containing a medium which is transformable from a first, reduced volume to a second, expanded volume;

transurethrally introducing the attenuation device within the patient'"'"'s bladder; and

transforming the medium from the first volume to the second volume to treat the patient.